Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881566 | 0.91 | MAPT (0.79) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL2469151 | 0.89 | MAPT (0.89) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL5054312 | 0.87 | MAPT (0.85) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL1951546 | 0.87 | MAPT (1.00) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL8683825 | 0.86 | MAPT (0.77) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL7937774 | 0.86 | MAPT (0.82) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL22495352 | 0.85 | MAPT (0.75) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| Hydrochloric Acid SCHEMBL6982145 | 0.85 | MAPT (0.74) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL27578576 | 0.85 | MAPT (0.74) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL223429 | 0.84 | MAPT (0.79) | MAPTRAB9AL3MBTL1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1861360-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101808-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | HRH3, HCRTR1, HRH4 | MAPT 925/4885RAB9A 1369/4885L3MBTL1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.